SCHEDULE 13G: Adage Capital Management Discloses 8.68% Passive Stake in Solid Biosciences Inc.
Beneficial Ownership Statement
Adage Capital Management, L.P. and its principals have filed a Schedule 13G, disclosing a passive beneficial ownership of 8.68% of Solid Biosciences Inc.'s common stock as of March 31, 2025.
Summary
- Adage Capital Management, L.P., along with its principals Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 6,729,484 shares of Solid Biosciences Inc. common stock.
- This ownership stake represents 8.68% of the company's total outstanding common stock.
- The percentage is calculated based on 77,492,959 shares of Common Stock outstanding as of March 3, 2025, as reported in Solid Biosciences Inc.'s Annual Report on Form 10-K filed on March 6, 2025.
- The shares are held for investment purposes in the ordinary course of business and are not intended to change or influence the control of Solid Biosciences Inc.
- Adage Capital Management, L.P. is a Delaware limited partnership, and Messrs. Atchinson and Gross are citizens of the United States.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain explicit positive or negative sentiment regarding the company's performance or outlook.
Positives
- The disclosure of a significant institutional investor, Adage Capital Management, holding a substantial stake (8.68%) can be interpreted as a vote of confidence in Solid Biosciences Inc.'s long-term prospects.
- The explicitly stated passive nature of the investment indicates no immediate intent to influence or change control, which may provide stability to the company's governance.
Future Outlook
NA
Industry Context
This filing indicates continued institutional interest in Solid Biosciences Inc., a company typically operating in the biotechnology or pharmaceutical sector, where significant institutional holdings are common for long-term investment strategies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder, potentially influencing investor confidence.
- Company Management: Awareness of a large, passive institutional investor on their shareholder register.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date as of which 77,492,959 shares of Common Stock were outstanding, as reported in the Company's Annual Report on Form 10-K. |
| 03/06/2025 | Date Solid Biosciences Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 03/31/2025 | Date of event which requires the filing of this statement. |
| 05/12/2025 | Date the Schedule 13G statement was signed and filed. |
Keywords
Solid Biosciences Inc., Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.